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CASE REPORT
Systemic sarcoidosis mimicking malignant metastatic
disease
Irena Hammen1*, David Lee Sherson1,2 and Jesper Roemhild Davidsen1
1Department of Pulmonal Medicine, Odense University Hospital, Odense, Denmark; 2Department of
Occupational Medicine, Odense University Hospital, Odense, Denmark
We present a case of systemic sarcoidosis involving the liver, pancreas, lungs, mediastinal and intraabdominal
lymph nodes and bones. Multiple organ system manifestations mimicked malignant metastatic disease. The
diagnosis was established with clinical, radiological, and pathological findings after neoplasm was ruled out
by pathological tests. The patient showed rapid symptom remission with systemic steroid treatment.
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S
arcoidosis is a systemic disease with unknown
aetiology characterised by pathological findings of
non-caseating epithelioid cell granulomas (1, 2).
Scandinavians and African Americans have the highest
geographic and ethnic incidence. In the United States,
an estimated incidence rate of five cases per 100,000
person-years for men and 6.3 per 100,000 person-years
for women has been reported (1). Danes seem to be more
commonly affected with an incidence of 7.2 per 100,000
person-years with around 400 incident cases per year (3).
The disease commonly affects young and middle-aged
adults and can involve multiple organ systems. The most
typical presentation is bilateral hilar lymphadenopathy,
pulmonary infiltration, ocular and various skin lesions.
The liver, spleen, other lymph nodes, salivary glands,
heart, nervous system, muscles, bones, and other organs
may seldom be involved (1, 2, 4). Cases with multiple
organ involvement sarcoidosis can present a diagnostic
challenge because they mimic many other diseases includ-
ing metastatic cancer.
Case report
A 45-year-old never-smoking male of Danish origin,
without any medical history, was referred acutely to our
emergency department with abdominal pain, vomiting,
and jaundice. He denied alcohol use and had no predis-
position to cancer, pulmonary, or gastrointestinal (GI)
diseases. As a gardener, he had no relevant occupational
exposures. During the last 4 weeks, he had suffered from
a lack of appetite, dull pain in the right upper abdominal
quadrant, and had an unintended weight loss of 10 kg.
He denied any respiratory symptoms, change in bowel
habits, melena, or fever.
At physical examination, he was chronically ill with a
body mass index of 18, jaundice and abdominal pain on
palpation of the upper abdominal quadrant. Pulmonary
and cardiac auscultation was normal and no exanthema
was present.
Laboratory tests showed leucopenia of 2.50109/L
(3.508.80109/L) and increased liver enzymes tests with
alanine transaminase of 441 IU/L (1070 IU/L), alkaline
phosphatase of 194 IU/L (35105 IU/L), bilirubin of
196 mmol/l (525 mmol/L), and lactate dehydrogenase of
218 U/L (105205 U/L). Pancreas amylase, gamma-
glutamyl transferase, C-reactive protein, haemoglobin,
thrombocyte concentration, calcium, and creatinine were
within normal limits. Because of the liver involvement,
hepatitis was suspected, but serology test for Hepatitis A,
B, C, HIV, and Leptospirosis were negative. There were
normal immunoglobulin subgroups and autoimmunologi-
cal tests, including anti-nuclear and anti-neutrophil cyto-
plasmic antibodies, which were negative. However, an
increased blood angiotensin-converting enzyme (ACE)
above 88 U/L (853 U/L) was observed.
Lung function tests showed normal ventilation and
diffusion parameters with forced expiratory volume in
1 second (FEV1) of 4.4l, corresponding to 102% of pre-
dicted; forced vital capacity (FVC) of 5.7l, corresponding
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to 105% of predicted; and lung diffusion of carbon mon-
oxide (DLCO) corresponding to 85% of predicted. Total
lung capacity was not measured.
Because of the biochemical signs of hepatitis, an
abdominal sonography was performed, uncovering lym-
phadenopathy in the lever hilus. The patient underwent
computer tomography (CT) of thorax and abdomen,
which revealed lesions in the pancreas, bilateral pulmon-
ary nodular infiltrates, as well as mediastinal and intraab-
dominal lymphadenopathy (Figs. 13).
As metastatic cancer was suspected, a whole-body 18
flour-deoxyglucose positron emission tomography (18-
FDG PET) scanning was performed, presenting multiple
pathological lesions in lungs, pancreas, lymph nodes, and
bones (Fig. 4).
A sonography-guided lever biopsy showed non-
caseating granulomatous inflammation. The patient un-
derwent further invasive procedures: bronchoscopy with
transbronchial biopsy (TBB), bronchoalveolar lavage
(BAL) with flowcytometry, endobronchial ultrasound
(EBUS) with transbronchial needle aspiration (TBNAB)
biopsy, and a bone marrow biopsy. None of the patholo-
gical tests revealed any malignant findings. Bronchoscopy
was without any macroscopic abnormalities. BAL flowcy-
tometry uncovered an overall lymphocytic inflammation
with a proportion of 51%, an increased CD4/CD8 ratio
of 5.4 without any eosinofilia or neutrofilia. Pathological
evaluation of the samples from the TBBs demonstrated
non-caseating granulomas and EBUS-TBNAB from the
mediastinal lymph nodes showed unspecific fibrosis.
Microbiological tests from the bronchoscopy specimens
did not reveal any respiratory infection (no growth of
bacteria in cultivation, negative tuberculosis tests includ-
ing cultivation, negative PCR tests concerning Legionella
pneumophila, Mycoplasma pneumonia, Chlamydia psittaci
et pneumoniae, and Pneumocystis jirovecii).
We considered the following differential diagnoses:
metastatic malignancy with unknown primary tumour,
liver diseases (hepatitis, both infectious and autoimmune,
biliary cirrhosis, and primary sclerosing cholangitis), in-
fectious diseases (leptospirosis, AIDS, and tuberculosis),
and autoimmune systemic diseases.
Based on the composite findings (increased blood
ACE, various FDG metabolic active lesions in the PET-
scanning, non-caseating inflammation in liver biopsy and
TBBs, lymphocytic inflammation with increased CD4/
CD8 ratio in BAL) and exclusion of other diseases capable
of producing a similar pathological and clinical picture,
a diagnosis of systemic sarcoidosis was well established.
The patient was treated with systemic prednisolone
(0.5 mg/kg/day37.5 mg/day), slowly tapering every
third week (25 mg/day for 3 weeks, then 12.5 mg for
3 weeks), until a fixed dose of 7.5 mg prednisolone/day
was reached. Three weeks into the treatment, blood tests
showed normalised ACE and liver function parameters.
At present we follow him in our respiratory outpatient
Fig. 1. CT Thorax showing bilateral pulmonary nodular
infiltrates.
Fig. 2. CT Thorax showing mediastinal lymphadenopathy.
Fig. 3. CT Abdomen showing lesions in the pancreas.
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clinic and plan to fully taper steroids according to the
disease activity.
Discussion
Sarcoidosis is a systemic disease, which in more than 90%
of the cases involves the respiratory system and thereby
manifests itself with pulmonary symptoms as dyspnoea
and coughing (1, 2, 4). Non-specific constitutional symp-
toms such as fever, fatigue, malaise, and weight loss occur
in about one-third of the patients as a result of increased
immunological activity (4). In nearly one-third of the cases,
the mediastinal lymph nodes are affected, giving rise to a
sense of non-specific intrathoracic soreness. Multiorgan
involvement is common while isolated extrapulmonary
disease is rather rare and is reported in only up to 10%
of the cases (1, 4). Cutaneous involvement is reported in
approximately 25% (1, 4), neuro and cardiac manifestation
in fewer than 10 and 5%, respectively, and ocular involve-
ment in up to 83% of the patients with sarcoidosis (1).
The incidence of GI tract involvement is less than
1.0% and can mimic Crohn’s disease or a GI fungal
infection (4). Hepatic sarcoidosis is mostly observed
in younger populations between 20 and 40 years of age,
where some 30% may present clinical symptoms such as
jaundice, nausea, vomiting, abdominal pain, and hepa-
tosplenomegaly (5, 6). In some cases, untreated hepatic
sarcoidosis can progress to liver cirrhosis with portal
hypertension and cholestasis. This makes it challenging
to distinguish hepatic sarcoidosis from hepatitis and
cirrhosis, especially in cases of primary biliary cirrhosis
and primary sclerosing cholangitis, where sarcoidosis
can coexist (5). Hepatic involvement rarely causes
hepatic failure, or increased mortality related to liver
dysfunction (4).
Rare cases of pancreatic involvement have been reported
although sparsely, for example, Shukla et al. reviewed
26 published cases with pancreatic manifestations from
1966 to 2007 (7). These cases included various abdominal
symptoms as unspecific pain, weight loss, vomiting, and
jaundice. Three patients even developed acute pancreatitis.
Symptoms were due to organ infiltration and compression
by enlarged lymph nodes (7).
Osseous involvement is relatively uncommon in sarcoi-
dosis. The incidence is reported between 1 and 14%. Small
bones of the hand and feet are most commonly involved,
but other skeletal manifestations were also reported (8).
As this case report illustrates, due to multisystem
involvement, systemic sarcoidosis can easily be mistaken
for other systemic and especially metastatic disease (9, 10).
It becomes even more challenging if the patient also has
a history of previous or ongoing neoplasm. Clinical
presentation with non-specific symptoms, such as weight
loss, pain, dyspnoea, and cough, can be found both in case
of malignancy and sarcoidosis.
The radiological presentation can also mimic malig-
nancy. Typical findings in thoracic imaging (chest X-
ray, CT-scanning, and high resolution CT-scanning) are
hilar or mediastinal nodal enlargement (stage I), combined
with parenchymal disease, that is, reticulonodular opa-
cities, irregular nodular thickening in a perilymphatic
distribution, nodules or large opacities, ground glass
opacities (stage II) only parenchymal lung disease (stage
III), and finally ongoing fibrosis with distorted lung
architecture (stage IV). Due to a hypermetabolic state
in active sarcoidosis, 18-FDG-PET scanning is not able
to distinguish between sarcoidosis and neoplastic disease.
Therefore, it is only recommended as a follow-up mon-
itoring examination in patients with already confirmed
sarcoidosis (11).
Granulomas are also sometimes found in lymph nodes
draining malignancies and in the margins of malignant
lesions including lymphoma and lung cancer. To make
it even more complicated, patients with malignancy can
at the same time develop sarcoidosis. The pathogenesis
of cancer-associated sarcoidosis is not known, but
has been observed with a coincidence of 14% in patients
Fig. 4. 18-FDG PET scanning presenting multiple patholo-
gical lesions in lungs, pancreas, lymph nodes, and bones.
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with malignancy (9, 10). The development of sarcoid-
like disease, secondary to chemotherapy, is noteworthy,
especially after therapy with the biological modifier
alpha-interferon. However, such pathological reactions
should not be mistaken with sarcoidosis (9, 12).
Further tests, such as an elevated ACE and CD4/CD8
ratio above 3.5 in BAL support the diagnosis of sarcoi-
dosis. However, the gold standard is cytohistological
confirmation. Biopsies can be performed from different
involved organs, but the diagnostic yield varies signifi-
cantly depending on disease manifestation. As almost
90% of sarcoidosis cases have pulmonary manifestations,
TBB was previously preferred as the invasive examina-
tion of choice with a diagnostic yield ranging from 40
to 90% due to variation in inter-operator experience (1).
As mediastinal lymphadenopathy appears in the acute
and symptomatic stage, EBUS-TBNAB and oesophagus
ultrasonographic (EUS) performed TBNABs are obvious
examination modalities with an evident sensitivity of
8994% (13) in recovering non-necrotizing granulomas
and thereby exceeding TBB. In addition, EBUS- and
EUS-TBNAB procedures are related to lower complica-
tion rates concerning pneumothorax and bleeding com-
pared to TBB (13). Analysis from BAL fluid obtained
during the bronchoscopy can be helpful, but may vary.
An analysis of CD4/CD8 ratios and percentages of
neutrophils and eosinophils revealed that a CD4/CD8
ratio of 4:1 or higher had a positive predictive value of 50%
of sarcoidosis, and apparently only related to sarcoidosis
(14). The same approach concerns a specific blood test
as ACE, which is elevated in about 60% of sarcoidosis
patients. These findings substantiate that elevated values
of CD4/CD8 ratio and ACE are only indicators of
sarcoidosis, but not diagnostic.
In conclusion, this case report illustrates that diagnos-
ing systemic sarcoidosis can be a challenging puzzle due to
the similarities between symptoms of systemic sarcoidosis
and malignant metastatic disease. Thus, it is important
to keep sarcoidosis in mind as a possible differential
diagnosis of neoplasma, especially in non-smoking young
adults with an abrupt disease course.
Conclusion
In summary, the diagnosis of sarcoidosis requires
compatible clinical symptoms, radiological findings,
pathological demonstration of non-caseating granulo-
mas, and exclusion of other diseases capable of produ-
cing a similar picture. Careful assessment particularly
applies to cases where extrathoracic or multiple organ
involvement is present.
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